Raffaele Addeo

Raffaele Addeo

Medical Oncologist

Precision Oncology

Frattamaggiore Hospital

Italy, Naples

Present Title & Affiliation

  • Director, Oncology Unit, Frattamaggiore Hospital, ASL Napoli 2 Nord, Italy
  • Chief, Departmental Unit of Oncology Day Hospital, ASL Napoli 2 Nord
  • Head, Inter-company Multidisciplinary Oncology Group (GOM) – ASL Napoli 2 Nord & AO Vanvitelli
  • Lung Cancer, Mesothelioma, Head and Neck Cancer, Melanoma, Thyroid Cancer
YearsDegree / TrainingInstitutionLocation

Education & Academic Training
1986Classical High School Diploma (60/60)Liceo Ginnasio “G.B. Vico”Nocera Inferiore, SA, Italy
1987 – 1993MD, Medicine and Surgery (110/110) – Thesis: Endocrine Mechanisms and Cancer: Identification of Immediate-Early Genes Activated by Estrogens During the First Phase of Cell CycleSecond University of Naples (SUN) – Faculty of Medicine and SurgeryNaples, Italy
1994 – 1998Specialization in Oncology (50/50) – Thesis: Estrogens and Breast Cancer: Cell Cycle Control by Transcriptional Regulation of hCCND1 GeneSecond University of Naples (SUN)Naples, Italy
2000 – 2004PhD in Pediatric Onco-Hematology – Project: Expression and Regulation of Bcl2, BAX and BclX Genes in the Apoptotic Pathway in Children with Acute Lymphoblastic LeukemiaPediatric Department of Onco-Hematology, Second University of NaplesNaples, Italy

Professional Experience
1994 – 1995AIRC Research FellowDepartment of General Pathology and Oncology, SUN (Profs. A. Weisz and F. Bresciani)Naples, Italy
1994Visiting ResearcherBiochemistry Department, University of Verona (Prof. Suzuki)Verona, Italy
1994Visiting ScientistIMT Marburg (Prof. Miguel Beato) – Project: Cell cycle control and breast cancer (in vivo genomic footprinting)Marburg, Germany
1995 – 1997Research FellowDepartment of General Pathology and Oncology, SUNNaples, Italy
1997Visiting ScientistNational Cancer Centre Research Institute (Dr. H. Esumi) – Project: VEGF and Nitric Oxide in HepatoblastomaKashiwa, Japan
1997 – 1998Oncology Training – Onco-Hematology Service (Prof. Abbadessa)SUNNaples, Italy
1998Oncology Training – Medical Oncology Division, “Cardarelli” HospitalNaples, Italy
1998Oncology Training – Pediatric Department of Onco-Hematology (Prof. M.T. Di Tullio)SUNNaples, Italy
1998 – 2000AGOP Fellowship, Pediatric Onco-HematologySUN (Prof. M.T. Di Tullio)Naples, Italy
2000 – 2004PhD Researcher, Pediatric Onco-HematologySUNNaples, Italy
2000 – 2005OncologistOncology Division, ASL NA3Naples, Italy
2004 – 2005Resident ResearcherPediatric Onco-Hematology, SUNNaples, Italy
2005 – PresentChief, Departmental Unit of Oncology Day HospitalASL NA2 NordNaples, Italy
2005 – PresentChief, Oncology DivisionFrattamaggiore Hospital, ASL NA2 NordNaples, Italy
2017 – 2021Head, Oncology Day Hospital – U.O. Complex of Oncology (Resolution 999/2017)ASL Napoli 2 NordNaples, Italy
2020 – 2021Manager, U.O.C. Oncology – Frattamaggiore Hospital (C.C.N.L. 2016/2018 Art. 22)ASL Napoli 2 NordNaples, Italy
2021 – PresentDirector, Oncology UnitFrattamaggiore Hospital, ASL Napoli 2 NordNaples, Italy
2021 – PresentHead, Inter-company GOM ASL NA2 Nord – AO Vanvitelli (Lung, Mesothelioma, H&N, Melanoma, Thyroid Cancers)ASL Napoli 2 NordNaples, Italy
2023 – PresentChief, Regional Project Line – Management and Monitoring of Chronic Patients’ Adherence to TherapyASL Napoli 2 NordNaples, Italy

Fellowships and Academic Distinctions
1995EMBO Fellowship – Genomic Sequencing and Footprinting in VivoEuropean Molecular Biology Organization
1998IEO Fellowship – Advanced Course: Colorectal CancerEuropean School of Oncology
2000AGOP Fellowship (awarded by public competition)Pediatric Onco-Hematology, SUN
2001 – 2004Teaching Assistant and Tutor – Pediatric Oncology CourseSUN, Prof. M.T. Di Tullio
2003 – PresentNational Molecular Biology AdvisorGITR (Italian Group for Rare Tumors) & AIEOP (Italian Pediatric Onco-Hematology Association)
2004Award for Outstanding Achievement9th World Congress on Advances in Oncology, Crete, Greece

Professional Memberships
American Association for Cancer Research (AACR)Member since 1998
Associazione Italiana di Oncologia Medica (AIOM)Member since 2002
Società Italiana per le Cure Palliative (SICP)Member since 2003
American Society of Clinical Oncology (ASCO)Member since 2005

Publications with Impact Factor

  1.  Ambrosino C, Cicatiello L, Cobellis G, Addeo R, Sica V, Bresciani F, Weisz A. Functional antagonism between the estrogen receptor and Fos in the regulation of c-fos proto-oncogene transcription. Molecular Endocrinology. 1993; 7:1472–1483.
  2.  Cicatiello L, Cobellis G, Addeo R, Papa M, Altucci L, Sica V, Bresciani F, LeMeur M, Kumar V, Chambon P, Weisz A. In vivo functional analysis of the mouse estrogen receptor gene promoter: a transgenic mouse model to study tissue-specific and developmental regulation of estrogen receptor gene transcription. Molecular Endocrinology. 1995; 9:1077–1090.
  3. Weisz A, Cicatiello L, Ambrosino C, Addeo R, Altucci L, Bonapace IM, Sica V, Bresciani F. Transcriptional mechanism for cell proliferation control by estrogen hormones. Biotechnology. 1994; 58.
  4. Addeo R, Cicatiello L, Altucci L, Pacilio C, Germano D, Bresciani F, Weisz A. Estrogen restores cell cycle progression in human breast cancer cells arrested in G1 by HMG-CoA reductase inhibitors. Tumori. 1995; 81(Suppl 4):131.
  5. Weisz A, Addeo R, Altucci L, Battista T, Boccia V, Cancemi M, Cicatiello L, Germano D, Mancini A, Pacilio C, Bresciani F. Molecular mechanisms for estrogen control of cell cycle progression during G1. In In Vivo Biology of Sex Steroid Hormone Action (H. Kuramoto et al., eds.). Churchill Livingstone, Tokyo, 1996:1–16.
  6. Addeo R, Altucci L, Battista T, Bonapace IM, Cancemi M, Cicatiello L, Germano D, Pacilio C, Salzano S, Bresciani F, Weisz A. Stimulation of human breast cancer MCF-7 cells with estrogen prevents cell cycle arrest by HMG-CoA reductase inhibition. Biochemical and Biophysical Research Communications (BBRC). 1996; 220:864–870.
  7. Altucci L, Addeo R, Cicatiello L, Dauvois S, Parker MG, Truss M, Beato M, Sica V, Bresciani F, Weisz A. 17β-estradiol induces cyclin D1 gene transcription, p36D1–p34cdk4 complex activation, and p105Rb phosphorylation during mitogenic stimulation of G1-arrested human breast cancer cells. Oncogene. 1996; 12:2315–2324.
  8. Bonapace IM, Addeo R, Altucci L, Cicatiello L, Bifulco M, Laezza C, Salzano S, Sica V, Bresciani F, Weisz A. 17β-estradiol overcomes a G1 block induced by HMG-CoA reductase inhibitors and fosters cell cycle progression without inducing ERK1/2 MAP kinase activation. Oncogene. 1996; 12:753–763.
  9. Altucci L, Addeo R, Cicatiello L, Germano D, Pacilio C, Battista T, Cancemi M, Belsito Petrizzi V, Bresciani F, Weisz A. Estrogen induces early and timed activation of cyclin-dependent kinases 4, 5, and 6 and increases cyclin mRNA expression in rat uterus. Endocrinology. 1997; 138:978–984.
  10. Esumi H, Addeo R, Chin K, Kurashima Y, Rimura H, Ogura T, Weisz A. Nitric oxide is a distinct mediator of the cellular reaction to hypoxia. In The Biology of Nitric Oxide, Part 6, S. Moncada (ed.), 1997.
  11. Weisz A, Addeo R, Chin K, D’Acquisto F, Rimura H, Esumi H. Transcriptional factor and human vascular endothelial growth factor gene expression by nitric oxide. In ADP-Ribose and Nitric Oxide, 1997.
  12. Pacilio C, Germano D, Addeo R, Altucci L, Belsito Petrizzi V, Cancemi M, Cicatiello L, Salzano S, Lallemand F, Michailides RJA, Bresciani F, Weisz A. Constitutive overexpression of cyclin D1 does not prevent inhibition of hormone-responsive human breast cancer cell growth by antiestrogen. Cancer Research. 1998; 58:871–876.
  13. Di Tullio MT, D’Angelo V, Casale F, Rinaldi B, Indolfi P, Addeo R, Martini A, Morgera C. Functional analysis of Bcl2 family genes in childhood lymphoblastic leukemia during glucocorticoid prephase. Medical and Pediatric Oncology.1999; 33:271.
  14. Kimura H, Weisz A, Kurashima Y, Hashimoto K, Ogura T, D’Acquisto F, Addeo R, Makuuchi M, Esumi H. Hypoxia response element of the vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: control of hypoxia-inducible factor-1 activity by nitric oxide. Blood. 2000; 95:189–197.
  15. Cicatiello L, Altucci L, Addeo R, Belsito Petrizzi V, Boccia V, Cancemi M, Germano D, Pacilio C, Salzano S, Bresciani F, Weisz A. The antiestrogen ICI 182,780 inhibits proliferation of human breast cancer cells by interfering with multiple estrogen-regulated processes required for cell cycle completion. Molecular and Cellular Endocrinology. 2000; 165:199–209.
  16. Casale F, Addeo R, D’Angelo V, Indolfi P, Poggi V, Del Prete S, Crisci S, Di Tullio MT. Determination of the in vivo effects of prednisone on Bcl-2 family protein expression in childhood acute lymphoblastic leukemia. International Journal of Oncology. 2003; 22:123–128.
  17. Del Prete S, Caraglia M, Russo D, Vitale G, Giuberti G, Marra M, D’Alessandro AM, Lupoli G, Addeo R, Facchini G, Rossiello R, Abruzzese A, Papasso E. Percutaneous ethanol injection efficacy in the treatment of large symptomatic thyroid cystic nodules: ten-year follow-up of a large series. Thyroid. 2002; 12(9):815–821.
  18. Addeo R, D’Angelo V, Crisci S, Martini A, Di Martino M, De Luca R, Di Tullio MT, Casale F, Indolfi P. Analysis of cyclin-dependent kinase inhibitors and p105Rb protein expression in childhood acute lymphoblastic leukemia at diagnosis and after prednisone treatment. International Journal of Molecular Medicine. 2003; 12(Suppl 1).
  19. Del Prete S, Caraglia M, Addeo R, Costanzo R, Faiola V, Facchini G. Pegylated liposomal doxorubicin plus temozolomide in the salvage treatment of brain metastases: a feasibility study. Annals of Oncology. 2003; 14(Suppl 4).
  20. Costanzo R, Caraglia M, D’Alessandro AM, Marra M, Giuberti G, Addeo R, Vitale G, Colao AM, Abruzzese A, Del Prete S. Combination of somatostatin analogues and Ras–ERK inhibitory agents in pancreatic adenocarcinoma cells.Annals of Oncology. 2003; 14(Suppl 4).
  21. Caraglia M, D’Alessandro AM, Addeo R, Marra M, Giuberti G, Tagliaferro P, Tassone P, Budillon A, Venuta S, Abruzzese A, Del Prete S. The synergism between pamidronate and FTI R155777 in inducing apoptosis of human epidermoid cancer cells is mediated by potentiation of Ras inactivation. Annals of Oncology. 2003; 14(Suppl 4).
  22. Addeo R, Caraglia M, Costanzo R, Faiola V, Facchini G, Del Prete S. Feasibility of biochemotherapy schedules in the treatment of non-Hodgkin’s lymphoma in elderly patients. Annals of Oncology. 2003; 14(Suppl 4).
  23. Indolfi P, Addeo R, Casale F, D’Angelo V, Pettinato G, Crisci S, D’Onofrio V, Alaggio R, Sabatino M, Di Martino M, Di Tullio MT. Mutational analysis of p53 and BAX genes in pediatric germ-cell tumors: a multicentric study. Medical and Pediatric Oncology. 2003; 41(4).
  24. Cicatiello L, Addeo R, Sasso A, Altucci L, Belsito Petrizzi V, Borgo R, Cancemi M, Caporali S, Caristi S, Scafoglio C, Teti D, Bresciani F, Perillo B, Weisz A. Estrogens and progesterone promote persistent CCND1 gene activation during G1 by inducing transcriptional derepression via c-Jun/c-Fos/estrogen-receptor complex assembly and recruitment of Cyclin D1 to its own promoter. Molecular and Cellular Biology. 2004; 24(16):7260–7274.
  25. Addeo R, Casale F, Caraglia M, D’Angelo V, Crisci S, Abruzzese A, Di Tullio MT, Indolfi P. Glucocorticoids induce G1 arrest of lymphoblastic cells through retinoblastoma protein (Rb1) dephosphorylation in childhood acute lymphoblastic leukemia in vivo. Cancer Biology & Therapy. 2004; 3(5):470–476.
  26. Addeo R, Caraglia M, Costanzo R, Faiola V, Montella L, Del Prete S. Oxaliplatin–rituximab combination in the treatment of intermediate/low-grade non-Hodgkin’s lymphoma of elderly patients. Oncology Reports. 2004; 12:135–140.
  27. Casale F, D’Angelo V, Addeo R, Caraglia M, Crisci S, Rondelli R, Di Tullio MT, Indolfi P. P-glycoprotein 170 expression and function as an adverse independent prognostic factor in childhood acute lymphoblastic leukemia.Oncology Reports. 2004; 12(6):1201–1207.
  28. Addeo R, Caraglia M, Baldi A, D’Angelo V, Casale F, Crisci S, Abbruzzese A, Campioni M, Di Tullio MT, Indolfi P. Prognostic role of Bcl-xL and p53 in childhood acute lymphoblastic leukemia. Cancer Biology & Therapy. 2005; 4(1):32–38.
  29. Montella L, Caraglia M, Addeo R, Costanzo R, Faiola V, Abbruzzese A, Del Prete S. Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert’s disease). Annals of Hematology. 2005; 84(3):192–193.
  30. Caraglia M, Addeo R, et al. Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumors. Cancer Chemotherapy and Pharmacology. 2005; 56:1–6.
  31. Caraglia M, Montella L, Addeo R, Costanzo R, Faiola V, Del Prete S, Baldi F, Baldi A, Abbruzzese A, Alloisio M. Conditions suggesting lymphoma: case 2. Mediastinal liposarcoma in a patient with previous testicular cancer. Journal of Clinical Oncology. 2005; 23(16):3844–3846.
  32. Vetrano A, Addeo R, Russo I, Meo G, De Rosa G, D’Anna F, Caraglia M. A case of clear renal-cell carcinoma associated with meningioma and verrucous carcinoma of the frontal region in an elderly patient. Journal of Experimental & Clinical Cancer Research. 2007; 26(1):157–159.
  33. Addeo R, Crisci S, D’Angelo V, Vincenzi B, Casale F, Pettinato G, Donofrio V, Boldrini R, Alaggio R, Collini P, Bertorelle R, Di Tullio MT, Caraglia M, Terenziani M, Lo Curto M, Indolfi P. BAX mutation and overexpression inversely correlate with immature phenotype and prognosis of childhood germ-cell tumors. Oncology Reports. 2007; 17(5):1155–1161.
  34. Addeo R, Caraglia M, Faiola V, Capasso E, Vincenzi B, Montella L, Guarrasi R, Caserta L, Del Prete S. Concomitant treatment of brain metastases with whole-brain radiotherapy and temozolomide is active and improves quality of life.BMC Cancer. 2007; 7:18.
  35. Addeo R, Montella L, Baldi A, Cennamo G, Guarrasi R, Faiola V, Caraglia M, Del Prete S. Atypical cutaneous lymphoid hyperplasia induced by chemotherapy in a patient with advanced colon carcinoma. Clinical Colorectal Cancer.2007; 6(10):728–730.
  36. Addeo R, Faiola V, Guarrasi R, Montella L, Vincenzi B, Capasso E, Cennamo G, Rotundo MS, Tagliaferri P, Caraglia M, Del Prete S. Liposomal pegylated doxorubicin plus vinorelbine as first-line chemotherapy for metastatic breast cancer in elderly women ≥ 65 years. Cancer Chemotherapy and Pharmacology. 2008; 62(2):285–292.
  37. Addeo R, Nocera V, Faiola V, Vincenzi B, Ferraro G, Montella L, Guarrasi R, Rossi E, Cennamo G, Tonini G, Capasso E, Santini D, Caraglia M, Del Prete S. Management of pain in elderly patients receiving zoledronic-acid infusion for bone metastases: a single-institution report. Supportive Care in Cancer. 2008; 16(2):209–214.
  38. Montella L, Addeo R, Caraglia M, Faiola V, Guarrasi R, Vincenzi B, Palmeri A, Capasso E, Nocera V, Tarantino L, Ariete M, Martorelli A, Del Prete S. Vascular endothelial growth factor monitoring in advanced hepatocellular carcinoma treated with radiofrequency ablation plus octreotide: a single-center experience. Oncology Reports. 2008; 20(2):385–390.
  39. Addeo R, De Rosa C, Faiola V, Leo L, Cennamo G, Montella L, Guarrasi R, Vincenzi B, Caraglia M, Del Prete S. Phase II trial of temozolomide using protracted low-dose schedule and whole-brain radiotherapy for non-small-cell lung cancer and breast-cancer patients with brain metastases. Cancer. 2008; 113(9):2524–2531.
  40. Montella L, Addeo R, Faiola V, Cennamo G, Guarrasi R, Capasso E, Mamone R, Michele C, Del Prete S. Zoledronic acid in metastatic chondrosarcoma and advanced sacrum chordoma: two case reports. Journal of Experimental & Clinical Cancer Research. 2009; 28:7.
  41. Addeo R, Caraglia M, Del Prete S. Highlights of the regional meeting of the Italian Southern Oncological Group (GOIM): focus on hepatocellular carcinoma—biological and clinical background, therapeutic guidelines, and perspectives. Expert Opinion on Investigational Drugs. 2009; 18(3):373–378.
  42. D’Angelo V, Crisci S, Casale F, Addeo R, Giuliano M, Pota E, Finsinger P, Baldi A, Rondelli R, Abbruzzese A, Caraglia M, Indolfi P. High ERK-1 activation and Gadd45a expression as prognostic markers in high-risk pediatric hemolymphoproliferative diseases. Journal of Experimental & Clinical Cancer Research. 2009; 28(1):39.
  43. Addeo R, Caraglia M, Del Prete S. Highlights of the Pananemia National Meeting of the Italian Southern Oncological Group (GOIM): pharmacological and molecular treatment of cancer-induced anemia. Expert Opinion on Pharmacotherapy. 2009; 10(6):1089–1093.
  44. Montella L, Addeo R, Guarrasi R, Cennamo G, Faiola V, Capasso E, Caraglia M, Del Prete S. Once-per-cycle pegfilgrastim in breast-cancer patients treated with docetaxel/epidoxorubicin/cyclophosphamide. European Journal of Cancer Care (England). 2009; 18(4):379–384.
  45. Addeo R, Abbruzzese A, Del Prete S. MUC2: a new key for pancreatic-cancer prognosis. Cancer Biology & Therapy.2009; 8(11):1000–1001.
  46. Addeo R, De Santi MS, Del Prete S, Caraglia M. Fotemustine and recurrent glioblastoma: possible new opportunities for an old drug. Cancer Chemotherapy and Pharmacology. 2009; 64(5):863–866.
  47. Montella L, Addeo R, Palmieri G, Caraglia M, Cennamo G, Vincenzi B, Guarrasi R, Mamone R, Faiola V, Frega N, Capasso E, Maiorino L, Leopardo D, Pizza C, Montesarchio V, Del Prete S. Zoledronic acid in the treatment of bone metastases from hepatocellular carcinoma: a case series. Cancer Chemotherapy and Pharmacology. 2009; 64(4):833–839.
  48. Vincenzi B, Santini D, Loupakis F, Addeo R, Rojas Llimpe FL, Baldi GG, Di Fabio F, Del Prete S, Pinto C, Falcone A, Tonini G. Cigarette-smoking habit may reduce benefit from cetuximab-based treatment in advanced colorectal-cancer patients. Expert Opinion on Biological Therapy. 2009; 9(8):945–949.
  49. Addeo R, Caraglia M, Bellini S, Abbruzzese A, Vincenzi B, Montella L, Miragliuolo A, Guarrasi R, Lanna M, Cennamo G, Faiola V, Del Prete S. Randomized phase III trial on gemcitabine versus mitomycin C in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. Journal of Clinical Oncology. 2009; 27(33):5439–5444.
  50. Marra M, Abbruzzese A, Addeo R, Del Prete S, Tassone P, Tonini G, Tagliaferri P, Santini D, Caraglia M. Cutting the limits of aminobisphosphonates: new strategies for potentiation of their antitumor effects. Current Cancer Drug Targets.2009; 9(7):791–800.
  51. Del Prete S, Montella L, Caraglia M, Maiorino L, Cennamo G, Montesarchio V, Piai G, Febbraro A, Tarantino L, Capasso E, Palmieri G, Guarrasi R, Bianco M, Mamone R, Savastano C, Pisano A, Vincenzi B, Sabia A, D’Agostino A, Faiola V, Addeo R. Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR study. Cancer Chemotherapy and Pharmacology. 2009 Dec 30.
  52. Caraglia M, Marra M, Naviglio S, Botti G, Addeo R, Abbruzzese A. Zoledronic acid: an unending tale for an antiresorptive agent. Expert Opinion on Pharmacotherapy. 2010; 11(1):141–154.
  53. Vincenzi B, Santini D, Russo A, Addeo R, Giuliani F, Montella L, Rizzo S, Venditti O, Frezza A M, Caraglia M, Colucci G, Del Prete S, Tonini G. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist. 2010 Jan 5.
  54. Addeo R, Caraglia M, Cerbone D, Frega N, Cimmino G, Abbruzzese A, Del Prete S. Panitumumab: a new frontier of target therapy for the treatment of metastatic colorectal cancer. Expert Review of Anticancer Therapy. 2010; 10(4):499–505.
  55. Montella L, Addeo R, Caraglia M, Del Prete S. Latest developments in targeted therapy for hepatocellular carcinoma.Expert Review of Anticancer Therapy. 2010; 10(10):1635–1646.
  56. Correale P, Remondo C, Carbone S F, Ricci V, Migali C, Martellucci I, Licchetta A, Addeo R, Volterrani L, Gotti G, Rotundo M S, Tassone P, Sperlongano P, Abbruzzese A, Caraglia M, Tagliaferri P, Francini G. Dose/dense metronomic chemotherapy with fractionated cisplatin and oral daily etoposide enhances the antiangiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell lung cancer patients. Cancer Biology & Therapy. 2010; 9(9):685–693.
  57. Addeo R, Sgambato A, Cennamo G, Montella L, Faiola V, Abbruzzese A, Capasso E, Leo L, Botti G, Caraglia M, Del Prete S. Low-dose metronomic oral vinorelbine as first-line treatment of elderly patients with metastatic breast cancer.Clinical Breast Cancer. 2010; 10(4):301–306.
  58. Addeo R, Caraglia M, De Santi M S, Montella L, Abbruzzese A, Parlato C, Vincenzi B, Carraturo M, Faiola V, Genovese M, Cennamo G, Del Prete S. Erratum to: A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma. Journal of Neuro-Oncology. 2010 Sep 21.
  59. Montella L, Addeo R, Caraglia M, Del Prete S. Latest developments in targeted therapy for hepatocellular carcinoma.Expert Review of Anticancer Therapy. 2010; 10(10):1635–1646.
  60. Addeo R, Caraglia M, Frega N, Del Prete S. Two faces for Janus: recombinant human erythropoiesis-stimulating agents and cancer mortality. Expert Review of Hematology. 2009; 2(5):513–515.
  61. Vincenzi B, Galluzzo S, Santini D, Rocci L, Loupakis F, Correale P, Addeo R, Zoccoli A, Napolitano A, Graziano F, Ruzzo A, Falcone A, Francini G, Dicuonzo G, Tonini G. Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients. Annals of Oncology. 2010 Nov 29.
  62. Addeo R, Caraglia M. The oral tyrosine-kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer? Expert Review of Anticancer Therapy. 2011; 11(2):139–142.
  63. Santini D, Vincenzi B, Adamo V, Addeo R, Fusco V, Russo A, Montemurro F, Roato I, Redana S, Lanzetta G, Satolli M A, Berruti A, Leoni V, Galluzzo S, Antimi M, Ferraro G, Rossi M, Del Prete S, Valerio M R, Marra M, Caraglia M, Tonini G. Cigarette-smoking habit does not reduce the benefit from first-line trastuzumab-based treatment in advanced breast cancer patients. Oncology Reports. 2011; 26(4):903–909.
  64. Correale P, Botta C, Basile A, Pagliuchi M, Licchetta A, Martellucci I, Bestoso E, Apollinari S, Addeo R, Misso G, Romano O, Abbruzzese A, Lamberti M, Luzzi L, Gotti G, Rotundo M S, Caraglia M, Tagliaferri P. Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell lung cancer patients. Cancer Biology & Therapy. 2011; 12(2):112–118.
  65. Caraglia M, Giuberti G, Marra M, Addeo R, Montella L, Murolo M, Sperlongano P, Vincenzi B, Naviglio S, Del Prete S, Abbruzzese A, Stiuso P. Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR. Cell Death & Disease. 2011; 2:e150.
  66. Addeo R, Caraglia M. Combining temozolomide with other antitumor drugs and target-based agents in the treatment of brain metastases: an unending quest or chasing a chimera? Expert Opinion on Investigational Drugs. 2011; 20(7):881–895.
  67. Santini D, Schiavon G, Vincenzi B, Gaeta L, Pantano F, Russo A, Ortega C, Porta C, Galluzzo S, Armento G, La Verde N, Caroti C, Treilleux I, Ruggiero A, Perrone G, Addeo R, Clezardin P, Muda A O, Tonini G. Receptor activator of NF-κB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast-cancer patients. PLoS One. 2011; 6(4):e19234.
  68. Romano O, Romano C, Cerbone D, Sperlongano P, Caserta L, Frega N, Cimmino G, D’Agostino A, Addeo R. Two case reports of biliary-tract injuries during laparoscopic cholecystectomy. ISRN Gastroenterology. 2011; 2011:868471.
  69. Addeo R, Sperlongano P, Montella L, Vincenzi B, Carraturo M, Iodice P, Russo P, Parlato C, Salzano A, Cennamo G, Lombardi A, Sperlongano R, Del Prete S, Caraglia M. Protracted low-dose oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment of breast-cancer patients with brain metastases. Cancer Chemotherapy and Pharmacology. 2012; 70(4):603–609.
  70. Santini D, Vincenzi B, Addeo R, Garufi C, Masi G, Scartozzi M, Mancuso A, Frezza A M, Venditti O, Imperatori M, Schiavon G, Bronte G, Cicero G, Recine F, Maiello E, Cascinu S, Russo A, Falcone A, Tonini G. Cetuximab rechallenge in metastatic colorectal-cancer patients: how to overcome acquired resistance? Annals of Oncology. 2012; 23(9):2313–2318
  71. Caraglia M, De Rosa G, Salzano G, Santini D, Lamberti M, Sperlongano P, Lombardi A, Abbruzzese A, Addeo R. Nanotech revolution for anticancer drug delivery through the blood–brain barrier. Current Cancer Drug Targets. 2012; 12(3):186–196.
  72. Caraglia M, Addeo R. Editorial: Target therapy in brain tumors and metastases. Current Cancer Drug Targets. 2012; 12(3):185.
  73. Santini D, Tampellini M, Vincenzi B, Ibrahim T, Ortega C, Virzi V, Silvestris N, Berardi R, Masini C, Calipari N, Ottaviani D, Catalano V, Badalamenti G, Giannicola R, Fabbri F, Venditti O, Fratto M E, Mazzara C, Latiano T P, Bertolini F, Petrelli F, Ottone A, Caroti C, Salvatore L, Falcone A, Giordani P, Addeo R, Aglietta M, Cascinu S, Barni S, Maiello E, Tonini G. Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone-metastasis study. Annals of Oncology. 2012; 23(8):2072–2077.
  74. Santini D, Addeo R, Vincenzi B, Calvieri A, Montella L, Silletta M, Caraglia M, Vespasiani U, Picardi A, Del Prete S, Tonini G. Exploring the efficacy and safety of single-agent sorafenib in Italian patients with hepatocellular carcinoma.Expert Review of Anticancer Therapy. 2012; 12(10):1283–1288.
  75. Vincenzi B, Frezza A M, Schiavon G, Spoto C, Silvestris N, Addeo R, Catalano V, Graziano F, Santini D, Tonini G. Identification of predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal-cancer patients treated with adjuvant FOLFOX IV. Supportive Care in Cancer. 2013; 21(5):1313–1319.
  76. Montella L, Addeo R, Cennamo G, Vincenzi B, Palmieri R, Sperlongano P, Sperlongano R, Iodice P, Russo P, Del Prete S. Sorafenib in elderly patients with advanced hepatocellular carcinoma: a case series. Oncology. 2013; 84(5):265–272.
  77. Addeo R, Zappavigna S, Luce A, Facchini S, Caraglia M. Chemotherapy in the management of brain metastases: the emerging role of fotemustine for patients with melanoma and NSCLC. Expert Opinion on Drug Safety. 2013; 12(5):729–740.
  78. Botta C, Barbieri V, Ciliberto D, Rossi A, Rocco D, Addeo R, Staropoli N, Pastina P, Marvaso G, Martellucci I, Guglielmo A, Pirtoli L, Sperlongano P, Gridelli C, Caraglia M, Tassone P, Tagliaferri P, Correale P. Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small-cell lung cancer patients. Cancer Biology & Therapy. 2013; 14(6):469–475.
  79. Vitale G, Lupoli G, Guarrasi R, Colao A, Dicitore A, Gaudenzi G, Misso G, Castellano M, Addeo R, Facchini G, Del Prete S, Caraglia M. Interleukin-2 and lanreotide in the treatment of medullary thyroid cancer: in vitro and in vivo studies. Journal of Clinical Endocrinology & Metabolism. 2013; 98(10):E1567–E1574.
  80. Vitagliano O, Addeo R, D’Angelo V, Indolfi C, Indolfi P, Casale F. The Bcl-2/Bax and Ras/Raf/MEK/ERK signaling pathways: implications in pediatric leukemia pathogenesis and new prospects for therapy. Expert Review of Hematology.2013; 6(5):587–597.
  81. Scarpati G D, Perri F, Ricciardiello F, Napolitano D, Addeo R. The best partner for radiotherapy after induction chemotherapy in a larynx preservation strategy. Oral Oncology. 2014; 50(1):e1–e2.
  82. Del Prete S, Cinieri S, Lorusso V, Maiorino L, Pizza C, Pisano A, Montesarchio V, Leo L, Savastano C, Pistolese G, Bianco M, Mabilia R, Tonachella R, Febbraro A, Manzione L, Palazzo S, Filippelli G, Vincenzi B, Barbato E, Cennamo G, Riccardi F, Misso G, Caraglia M, Addeo R. Impact of anemia management with erythropoietin on psychologic distress in cancer patients: results of a multicenter patient survey. Future Oncology. 2014; 10(1):69–78.
  83. Addeo R, Perri F, Parlato C, Della Vittoria G. ASCO 2013: Bevacizumab and glioblastoma—a marriage dissolution?Current Medical Research & Opinion. 2014; 30(9):1871–1873.
  84. Addeo R, Zappavigna S, Parlato C, Caraglia M. Erlotinib: early clinical development in brain cancer. Expert Opinion on Investigational Drugs. 2014; 23(7):1027–1037.
  85. Addeo R, Napolitano A, Montella L, Ricciardiello F. Squamous cell carcinoma of the tongue in a female with advanced breast cancer: a case report of an elderly patient presenting with two types of cancer. Oncology Letters. 2014; 8(1):235–237.
  86. Santini D, Pantano F, Riccardi F, Di Costanzo G G, Addeo R, Guida F M, Ceruso M S, Barni S, Bertocchi P, Marinelli S, Marchetti P, Russo A, Scartozzi M, Faloppi L, Santoni M, Cascinu S, Maiello E, Silvestris F, Tucci M, Ibrahim T, Masi G, Gnoni A, Comandone A, Fazio N, Conti A, Imarisio I, Pisconti S, Giommoni E, Cinieri S, Catalano V, Palmieri V O, Infante G, Aieta M, Trogu A, Gadaleta C D, Brunetti A E, Lorusso V, Silvestris N. Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone-metastasis survey. PLoS One. 2014; 9(8):e105268.
  87. D’Angelo V, Ramaglia M, Iannotta A, Addeo R. Pharmacogenetics of methotrexate in pediatric hematological neoplasms: does it need a personalized regimen based on MTHFR polymorphisms? Expert Review of Hematology. 2014; 7(5):517–519.
  88. Ascierto P A, Addeo R, Cartenì G, Daniele B, De Laurentis M, Ianniello G P, Morabito A, Palmieri G, Pepe S, Perrone F, Pignata S, Montesarchio V. The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014. Journal of Translational Medicine. 2014; 12:291.
  89. Stiuso P, Potenza N, Lombardi A, Ferrandino I, Monaco A, Zappavigna S, Vanacore D, Mosca N, Castiello F, Porto S, Addeo R, Del Prete S, De Vita F, Russo A, Caraglia M. MicroRNA-423-5p promotes autophagy in cancer cells and is increased in serum from hepatocarcinoma patients treated with sorafenib. Molecular Therapy – Nucleic Acids. 2015; 4:e233.
  90. Addeo R, Iodice P, Maiorino L, Febbraro A, Incoronato P, Pisano A, Bianco M, Mabilia R, Riccardi F, Del Prete S. Acceptance and adherence of oral endocrine therapy in women with metastatic breast cancer: EXACampania Group study. The Breast Journal. 2015; 21(3):326–328.
  91. Cazzaniga M E, Camerini A, Addeo R, Nolè F, Munzone E, Collovà E, Del Conte A, Mencoboni M, Papaldo P, Pasini F, Saracchini S, Bocci G. Metronomic oral vinorelbine in advanced breast and non-small-cell lung cancer: current status and future development. Future Oncology. 2016; 12(3):373–387.
  92. Della Vittoria Scarpati G, Perri F, Pisconti S, Costa G, Ricciardiello F, Del Prete S, Napolitano A, Carraturo M, Mazzone S, Addeo R. Concomitant cetuximab and radiation therapy: a promising strategy for locally advanced inoperable nonmelanoma skin carcinomas. Molecular and Clinical Oncology. 2016; 4(4):467–471.
  93. Santini D, Barni S, Intagliata S, Falcone A, Ferraù F, Galetta D, Moscetti L, La Verde N, Ibrahim T, Petrelli F, Vasile E, Ginocchi L, Ottaviani D, Longo F, Ortega C, Russo A, Badalamenti G, Collovà E, Lanzetta G, Mansueto G, Adamo V, De Marinis F, Satolli M A, Cantile F, Mancuso A, Tanca F M, Addeo R, Russano M, Sterpi M, Pantano F, Vincenzi B, Tonini G. Corrigendum: Natural history of non-small-cell lung cancer with bone metastases. Scientific Reports. 2016; 6:22205.
  94. Addeo R, Caraglia M, Iuliano G. Pembrolizumab: the value of PD-L1 biomarker in head and neck cancer. Expert Opinion on Biological Therapy. 2016; 16(9):1075–1078.Montella L, Palmieri G, Addeo R, Del Prete S. Hepatocellular carcinoma: will novel targeted drugs really impact the next future? World Journal of Gastroenterology. 2016; 22(27):6114–6126.
  95. Boccellino M, Quagliuolo L, Alaia C, Grimaldi A, Addeo R, Nicoletti G F, Kast R E, Caraglia M. The strange connection between EGFR tyrosine-kinase inhibitors and dapsone: from rash mitigation to increased antitumor activity.Current Medical Research & Opinion. 2016; 32(11):1839–1848.
  96. Del Prete S, Cennamo G, Leo L, Montella L, Vincenzi B, Biglietto M, Andreozzi F, Prudente A, Iodice P, Savastano C, Nappi A, Montesarchio V, Addeo R. Adherence and safety of regorafenib for metastatic colorectal cancer: an observational real-life study. Future Oncology. 2017; 13(5):415–423.
  97. Perri F, Longo F, Giuliano M, Sabbatino F, Favia G, Ionna F, Addeo R, Della Vittoria Scarpati G, Di Lorenzo G, Pisconti S. Epigenetic control of gene expression: potential implications for cancer treatment. Critical Reviews in Oncology/Hematology. 2017; 111:166–177.Addeo R. A new frontier for targeted therapy in NSCLC: clinical efficacy of pembrolizumab in PD-1 inhibition. Expert Review of Anticancer Therapy. 2017; 17(3):199–201.
  98. Perri F, Addeo R, Conson M, Faiella A, Scarpati G D V, Torre G, Di Biase A, Romanelli P, Buonerba C, Di Lorenzo G, Daponte A, Caponigro F, Pisconti S, Pacelli R, Ravo V, Muto P, Solla R. Locally advanced paranasal sinus carcinoma: a study of 30 patients. Oncology Letters. 2017; 13(3):1338–1342.
  99. Scarpati G D V, Perri F, Ferro M, Cavaliere C, Facchini G, Caraglia M, Zappavigna S, Addeo R. Vinflunine and bladder cancer: present and future indications. Translational Medicine Reports. 2017; 1:6397.
  100. Perri F, Longo F, Della Vittoria Scarpati G, Pisconti S, Longo V, Addeo R, Carducci F, Buonerba C, Fulciniti F, Solla R. Metastatic HPV-related oropharyngeal carcinoma cured with chemoradiotherapy: importance of pretherapy biomolecular assessment. Clinical Case Reports. 2017; 6(1):56–62.
  101. Caponigro F, Ionna F, Scarpati G D V, Longo F, Addeo R, Manzo R, Muto P, Pisconti S, Leopaldi L, Perri F. Translational research: a future strategy for managing squamous cell carcinoma of the head and neck? Anticancer Agents in Medicinal Chemistry. 2018; 18(9):1220–1227.
  102. Addeo R, Cimmino G. Skin toxicity and anti-EGFR therapy: a mock trouble for elderly and frail patients with metastatic colorectal cancer. Annals of Hematology & Oncology. 2018; 5(6):1213.
  103. Ricciardiello F, Addeo R, Di Lullo A M, Abate T, Mazzone S, Oliva F, Motta G, Caraglia M, Mesolella M. Adenoid cystic carcinoma of the larynx in a 70-year-old patient: a case report. Oncology Letters. 2018; 16(3):2783–2788.
  104. Riccardi F, Colantuoni G, Diana A, Mocerino C, Cartenì G, Lauria R, Febbraro A, Nuzzo F, Addeo R, Marano O, Incoronato P, De Placido S, Ciardiello F, Orditura M. Exemestane and everolimus combination treatment of hormone receptor–positive, HER2-negative metastatic breast cancer: a retrospective multicenter study from Campania Region (Southern Italy) focused on activity, efficacy, and safety. Molecular and Clinical Oncology. 2018; 9(3):255–263.
  105. Addeo R, Montella L, Mastella A, Vincenzi B, Mazzone S, Ricciardiello F, Del Prete S. Maintenance therapy with biweekly cetuximab: optimizing schedule can preserve activity and improve compliance in advanced head and neck cancer. Oncology. 2018; 95(6):353–359.
  106. Addeo R, Ghiani M, Merlino F, Ricciardiello F, Caraglia M. CheckMate-141 trial: all that glitters is not gold. Expert Opinion on Biological Therapy. 2019; 19(3):169–171.
  107. Addeo R, Caraglia M, Vincenzi B, Luce A, Montella L, Mastella A, Mazzone S, Ricciardiello F, Carraturo M, Del Prete S, Sperlongano P. Efficacy and safety of cetuximab plus radiotherapy in cisplatin-unfit elderly patients with advanced squamous cell carcinoma of the head and neck: a retrospective study. Chemotherapy. 2019; 64(1):48–56.
  108. Addeo R, Lamberti G, Simonetti G, Iodice P, Marinelli A, Montella L, Cappabianca S, Gaviani P, Caraglia M, Del Prete S, Silvani A. Biweekly fotemustine schedule for recurrent glioblastoma in the elderly: activity and toxicity assessment of a multicenter study. CNS Oncology. 2019; 8(2):CNS32.
  109. Rosati G, Addeo R, Aprile G, Avallone A, Bilancia D, Brugnatelli S, Buccafusca G, Carlomagno C, Cordio S, Delfanti S, Dell’Aquila E, Di Bisceglie M, Di Donato S, Di Stasi A, Germano D, Giuliani F, Granetto C, Latiano T P, Leo S, Tralongo P, Stroppolo M E, Venturini F, Bianco S. Italian survey on cetuximab-based therapy in elderly patients with metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology. 2019 Sep 6.
  110. Del Prete S, Caraglia M, Luce A, Montella L, Galizia G, Sperlongano P, Cennamo G, Lieto E, Capasso E, Fiorentino O, Aliberti M, Auricchio A, Iodice P, Addeo R. Clinical and pathological factors predictive of response to neoadjuvant chemotherapy in breast cancer: a single-center experience. Oncology Letters. 2019; 18(4):3873–3879.
  111. Caraglia M, Correale P, Giannicola R, Staropoli N, Botta C, Pastina P, Nesci A, Caporlingua N, Francini E, Ridolfi L, Mini E, Roviello G, Ciliberto D, Agostino R M, Strangio A, Azzarello D, Nardone V, Falzea A, Cappabianca S, Bocchetti M, D’Arrigo G, Tripepi G, Tassone P, Addeo R, Giordano A, Pirtoli L, Francini G, Tagliaferri P. GOLFIG chemo-immunotherapy in metastatic colorectal cancer patients: a critical review with long-term follow-up. Frontiers in Oncology. 2019; 9:1102.
  112. Lombardi A, Russo M, Luce A, Morgillo F, Tirino V, Misso G, Martinelli E, Troiani T, Desiderio V, Papaccio G, Iovino F, Argenziano G, Moscarella E, Sperlongano P, Galizia G, Addeo R, Necas A, Necasova A, Ciardiello F, Ronchi A, Caraglia M, Grimaldi A. Comparative study of NGS platform Ion Torrent Personal Genome Machine and Therascreen Rotor-Gene Q for the detection of somatic variants in cancer. High Throughput. 2020; 9(1):4.
  113. Cicero G, Addeo R, De Luca R, Lo Re G, Gulotta L, Marchesa P, Gulotta G. TAS-102 in metastatic colorectal cancer: efficacy, tolerability, and quality of life in heavily pretreated elderly patients — a real-life study. Drugs in Context.2020; 9:2020-6-3.
  114. Ricciardiello F, Bocchetti M, Pellini R, Palladino R, Caraglia M, Boscaino A, Petruzzi G, Romano F J, Chiurazzi B, Addeo R, Mazzone S, Mesolella M, Oliva F, Iorio B. Sarcomatoid larynx carcinoma: differential clinical evolution and statistical considerations. American Journal of Otolaryngology. 2021; 42(3):102934.
  115. Addeo R. Silibinin: a new opportunity for the treatment of brain metastasis from lung cancer. Journal of Experimental Pharmacology. 2021; 13:901–903.
  116. Ricciardiello F, Falco M, Tortoriello G, Riccardi F, Pellini R, Iorio B, Russo G, Longo G, Coppola C, Takeuchi T, Grimaldi A, Abate M, Scrima M, Cossu A M, Addeo R, Ottaiano A, Scarpa A, Boscaino A, Motta G, Caraglia M, Bocchetti M, Misso G. Poorly differentiated neuroendocrine larynx carcinoma: clinical features and miRNA signature — a new goal for early diagnosis and therapy? Journal of Clinical Medicine. 2021; 10(9):2019.
  117. De Luca R, Lo Coco G, Addeo R, Fattoruso S I S, Auriemma A, Paci R, Mistretta O, Epifanio M S, Salvato A, D’Agostino A, Cicero G. Quality of life in patients with severe skin reactions during first-generation EGFR inhibitor monoclonal antibody therapy (experience with cetuximab). World Journal of Oncology. 2021; 12(4):104–110.
  118. Fattoruso S I S, De Luca R, Grassadonia A, Evola S, Salvato A, Addeo R, Cicero G. Non-pegylated liposomal doxorubicin plus cyclophosphamide as first-line therapy in elderly women with HER2-negative metastatic breast cancer.Clinica Terapeutica. 2022; 173(2):121–127.
  119. Caiazzo M, Golino L, Addeo R, Fardello F, Russo G, Imperatore F. A delayed complication of port-a-cath insertion via subclavian venous access: case report of “pinch-off syndrome”. International Journal of Surgery Case Reports. 2022; 94:107039.
  120. Falco M, Tammaro C, Takeuchi T, Cossu A M, Scafuro G, Zappavigna S, Itro A, Addeo R, Scrima M, Lombardi A, Ricciardiello F, Irace C, Caraglia M, Misso G. Overview on molecular biomarkers for laryngeal cancer: looking for new answers to an old problem. Cancers (Basel). 2022; 14(7):1716.
  121. Zito Marino F, Amato M, Ronchi A, Panarese I, Ferraraccio F, De Vita F, Tirino G, Martinelli E, Troiani T, Facchini G, Pirozzi F, Perrotta M, Incoronato P, Addeo R, Selvaggi F, Lucido F S, Caraglia M, Savarese G, Sirica R, Casillo M, Lieto E, Auricchio A, Cardella F, Docimo L, Galizia G, Franco R. Microsatellite status detection in gastrointestinal cancers: PCR/NGS is mandatory in negative or patchy MMR immunohistochemistry. Cancers (Basel). 2022; 14(9):220.
  122. Caiazzo M, Golino L, Addeo R, Fardello F, Russo G, Imperatore F. A delayed complication of port-a-cath insertion via subclavian venous access: case report of “pinch-off syndrome”. International Journal of Surgery Case Reports. 2022; 94:107039.
  123. Amato M, Franco R, Facchini G, Addeo R, Ciardiello F, Berretta M, Vita G, Sgambato A, Pignata S, Caraglia M, Accardo M, Zito Marino F. Microsatellite instability: from detection implementation to prognostic and predictive role in cancers. International Journal of Molecular Sciences. 2022; 23(15):8726.
  124. Addeo R, Pompella L, Vitale P, Fattoruso S I S, Di Giovanni I, Perri F, Caraglia M, Fasano M, Arigliani R. The art of counseling in the treatment of head and neck cancer: exploratory investigation among perceptions of health professionals in Southern Italy. Current Oncology. 2022; 29(9):6277–6286.
  125. Fasano M, Pirozzi M, Famiglietti V, Facchini S, Caterino M, Caroprese M, Barillaro A, Di Giovanni I, Auriemma A, Fattoruso S I, Somma T, Solari D, Bocchetti M, Conson M, Pacelli R, Ciardiello F, Addeo R. Clinical activity of regorafenib in elderly patients with recurrent glioblastoma. Molecular and Clinical Oncology. 2023; 18(2):9.
  126. De Falco V, Vitale P, Brancati C, Cicero G, Auriemma A, Addeo R. Prognostic value of diabetes and metformin use in a real-life population of head and neck cancer patients. Frontiers in Medicine (Lausanne). 2023; 10:1252407.
  127. Vitale P, Bocchino I, De Falco V, Auletta G, Di Giovanni I, Bocchetti M, Auriemma A, Conchiglia R, Addeo R. Utility of psychotherapy assessed with Kessler scale in cancer patients undergoing systemic oncologic treatment: a mono-institutional experience. Chinese Clinical Oncology. 2023; 12(4):35.